论文部分内容阅读
目的:评价肝癌患者化疗前后血清可溶性Apo-1/Fas(sApo-1/Fas)水平变化的临床意义。方法:采用酶联免疫吸附试验法(ELISA)检测30例正常人及58例肝癌患者化疗前后血清sApo-1/Fas水平,并作对比分析。结果:肝癌患者血清sApo-1/Fas水平明显高于正常对照组(P<0.01),Ⅲ期肝癌血清sApo-1/Fas水平明显高于Ⅱ期(P<0.01),化疗后有效(完全缓解和部分缓解)患者血清sApo-1/Fas水平明显低于化疗前者(P<0.01),血清sApo-1/Fas水平与肝癌患者性别、年龄均无相关。结论:血清sApo-1/Fas可能参与调控肝癌的发生、发展过程,可作为化疗疗效和判断预后观察指标。
Objective: To evaluate the clinical significance of serum soluble Apo-1 / Fas (sApo-1 / Fas) levels in patients with hepatocellular carcinoma before and after chemotherapy. Methods: Serum sApo-1 / Fas levels in 30 normal and 58 HCC patients before and after chemotherapy were detected by enzyme linked immunosorbent assay (ELISA), and compared. Results: Serum levels of sApo-1 / Fas in patients with hepatocellular carcinoma were significantly higher than those in normal controls (P <0.01). Serum sApo-1 / Fas levels in patients with stage Ⅲ hepatocellular carcinoma were significantly higher than those in patients in stage Ⅱ (P <0.01) (P <0.01). Serum sApo-1 / Fas levels were not associated with gender and age of patients with HCC. Conclusion: Serum sApo-1 / Fas may be involved in the regulation of the occurrence and development of hepatocellular carcinoma, which can be used as an indicator of efficacy and predictive prognosis of chemotherapy.